Royalty Pharma
RPRX
$26.61
Share price
-1.15%
Change (1 day)
-16.58%
Change (1 year)
Categories
Royalty Pharma (RPRX) - Total debt
Total debt on the balance sheet as of March 2024 : $6.13 B
According to Royalty Pharma's latest financial reports the company's total debt is $6.13 B. A company’s total debt is the sum of all current and non-current debts.
Royalty Pharma - Total debt on balance sheet (from 2019 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $6.13 B | -13.79% |
| 2022-12-31 | $7.11 B | 0.29% |
| 2021-12-31 | $7.09 B | 22% |
| 2020-12-31 | $5.81 B | -6.76% |
| 2019-12-31 | $6.23 B | -4.31% |
| 2018-12-31 | $6.51 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | $14.58 B | 137.58% | 🇺🇸 USA |
 Eli Lilly LLY | $26.21 B | 326.94% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.28 B | -95.35% | 🇺🇸 USA |